Related Experiment Videos
[Molecule targeted therapy for hematological malignancies]
1Dept. of Infectious Diseases, Nagoya University School of Medicine.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 13, 2001
Summary
Molecular targeted therapy has advanced cancer treatment, offering new hope for hematological malignancies. This review covers targeted drugs like all-trans retinoic acid for acute promyelocytic leukemia and tyrosine-kinase inhibitors for chronic myeloid leukemia.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Context:
- Significant advancements in understanding molecular mechanisms of hematological malignancies over the last two decades.
- Emergence of mechanism-based therapies to enhance chemotherapy effectiveness.
- Growing knowledge of specific molecular targets in leukemia subtypes.
Purpose:
- To review the current landscape of molecule-targeted therapy for hematological malignancies.
- To highlight key examples of successful targeted treatments.
- To discuss the impact of molecular insights on therapeutic strategies.
Summary:
- All-trans retinoic acid (ATRA) targets the PML-RAR alpha oncoprotein in acute promyelocytic leukemia (APL), demonstrating differentiation therapy.
- Tyrosine-kinase inhibitors have shown promising results in treating chronic myeloid leukemia.
- Humanized monoclonal antibodies targeting differentiation antigens are recognized for their clinical effectiveness.
Impact:
- Molecule-targeted therapy represents a paradigm shift in cancer treatment, moving beyond traditional chemotherapy.
- These targeted approaches offer improved efficacy and potentially reduced toxicity for patients with hematological malignancies.
- Continued research into molecular mechanisms promises further development of novel, mechanism-based therapies.